



## Arbutus to Participate in Two Upcoming Investor Conferences

September 3, 2024

WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (CHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:

- **H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference:** Formal Presentation on September 9, 2024 at 8:00 am ET
- **Baird Global Healthcare Conference:** Fireside Chat on September 10, 2024 at 8:30 am ET

To access the live webcast of the presentation and fireside chat please visit: <https://investor.arbutusbio.com/events-presentations>. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

### About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (CHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### Contact Information

#### Investors and Media

Lisa M. Caperelli  
Vice President, Investor Relations  
Phone: 215-206-1822  
Email: [lcaperelli@arbutusbio.com](mailto:lcaperelli@arbutusbio.com)